577. Safety and Tolerability of Long Term Use of Tedizolid for Treatment of Nontuberculous Mycobacterial Infections
Session: Poster Abstract Session: Non-Tuberculosis Mycobacterial
Thursday, October 27, 2016
Room: Poster Hall
Posters
  • TKIM_Tedizolid_IDWeekPoster_final.pdf (333.1 kB)
  • Background:

    Tedizolid is a second-generation oxazolidionone and is in the same class as linezolid. Linezolid is associated with poor long-term tolerability due to bone marrow suppression, drug interactions, and peripheral and optic neuropathy. Tedizolid is thought to have less frequent dosing, minimal interaction with serotonergic agents, and less adverse events associated with the impairment of mitochrondrial protein synthesis that lead to myelosuppression, peripheral and optic neuropathy compared to linezolid. Currently, no safety and tolerability data exist for tedizolid usage for mycobacterial infections >14 days.

    Methods:

    Pharmacy and medical records were reviewed to include all patients who received tedizolid for at least 14 days for nontuberculous mycobacterial (NTM) infections; clinical and demographic information were abstracted from medical records.

    Results:

    We identified 24 patients, 20 of whom had pulmonary NTM disease and 4 with disseminated disease; mean age was 48 years (range 6 - 71). Median duration of tedizolid was 101 days (range, 15 - 369 days). Overall, 14 (58%) patients experienced an adverse event: 5 (21 %) peripheral neuropathy, 3 (13%) patients reported muscle rigidity with concomitant use of metoclopramide suggestive of serotonin toxicity. Additional adverse effects were as follows: 1 (4%) lymphopenia, 1 (4%) thrombocytopenia, 1 (4%) anemia, 3 (13%) diarrhea, 3 (13%) nausea/vomiting, and 2 (8%) liver enzyme abnormalities. No patients reported optic neuritis.

    Conclusion:

    Post-marketing safety and tolerability of tedizolid in this patient sample seem comparable to prior reports regarding linezolid. However, further analysis is needed to confirm these findings.

    Tiffany Kim, PharmD1, Aprielle Wills, MPH2, Alexandra Markus, PharmD1,3, D. Rebecca Prevots, PhD, MPH2 and Kenneth N. Olivier, MD, MPH4, (1)Department of Pharmacy, Clinical Center, National Institute of Health, Bethesda, MD, (2)Epidemiology Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD, (3)School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, (4)Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD

    Disclosures:

    T. Kim, None

    A. Wills, None

    A. Markus, None

    D. R. Prevots, None

    K. N. Olivier, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.